Radnet Stock Price, News & Analysis

RadNet (NASDAQ: RDNT) will host a conference call to discuss its third quarter 2025 financial results on Monday, November 10, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Investors can join by phone at 844-826-3035 (U.S.) or 412-317-5195 (international).

There will be simultaneous and archived webcasts at https://viavid.webcasts.com/starthere.jsp?ei=1740003&tp_key=5e6a1fc906. An archived phone replay will be available via 844-512-2921 (U.S.) or 412-317-6671 (international) using passcode 10204112.

RadNet (NASDAQ:RDNT), a leading provider of diagnostic imaging services, announced its participation in the upcoming Jefferies Healthcare Services Conference. Dr. Howard Berger, President and CEO, and Mark Stolper, Executive Vice President and CFO, will present on September 29, 2025, at 1:50 PM Central Time in Nashville, TN.

Investors can access the presentation through a simultaneous webcast, which will also be archived for future viewing, available on the company's website under the "About RadNet" section and through the provided webcast link.

RadNet (NASDAQ: RDNT), a leading provider of outpatient diagnostic imaging services, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's senior management team, including CEO Dr. Howard Berger, CFO Mark Stolper, and EVP Mital Patel, will present on September 9th, 2025, at 4:50 PM ET at the Sheraton New York Times Square Hotel.

The presentation will be accessible through a simultaneous webcast and will also be archived for future viewing through the provided webcast link.

RadNet (NASDAQ:RDNT), a leading outpatient diagnostic imaging services provider, reported record Q2 2025 results with total revenue increasing 8.4% to $498.2 million and Adjusted EBITDA growing 12.3% to $81.2 million. The company's Digital Health segment saw significant growth with revenue up 30.9% to $20.7 million.

Advanced imaging volumes showed strong performance, with MRI volume up 9.0%, CT volume up 8.1%, and PET/CT volume surging 22.4%. The company achieved Adjusted Earnings of $23.8 million ($0.31 per share), compared to $12.0 million ($0.16 per share) in Q2 2024.

Based on strong performance, RadNet revised its 2025 guidance upward, with total net revenue now projected at $1.85-1.90 billion and Adjusted EBITDA expected between $271-279 million.

DeepHealth, a RadNet (NASDAQ: RDNT) subsidiary, has received FDA 510(k) clearance for TechLive™, a remote scanning solution for MR, CT, PET/CT, and Ultrasound procedures. The vendor-agnostic platform enables centralized operation and supervision of multiple imaging systems simultaneously.

During a pilot deployment at 64 New York facilities, TechLive™ helped achieve a 42% reduction in MRI room closure hours in Q2 2025 compared to Q2 2024. The system has already been implemented across over 300 RadNet imaging systems, improving operational efficiency and increasing access to complex procedures.

RadNet (NASDAQ:RDNT), a leading provider of diagnostic imaging services and digital health solutions, has scheduled its second quarter 2025 financial results conference call for Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors can participate by dialing 844-826-3035 (US) or 412-317-5195 (International). A simultaneous webcast will be available, and an archived replay can be accessed using the passcode 10201853.

RadNet (NASDAQ:RDNT) has completed the acquisition of iCAD (NASDAQ:ICAD), a global leader in AI-powered breast health solutions, through its wholly-owned subsidiary DeepHealth. The strategic acquisition integrates iCAD's extensive AI portfolio for breast cancer detection with DeepHealth's screening solutions, expanding their reach to over 10 million mammograms annually.

iCAD's technology portfolio, deployed in more than 50 countries across 1,500+ healthcare provider locations, includes solutions for breast cancer detection, risk evaluation, breast density, and arterial calcification assessment. The combination aims to enhance AI model performance and accelerate the adoption of advanced breast cancer screening technologies worldwide, particularly in underserved communities.

RadNet (NASDAQ:RDNT), a leading outpatient diagnostic imaging services provider, announced that Regal Medical Group, Lakeside Community Healthcare, and ADOC Medical Group will include RadNet's Enhanced Breast Cancer Detection (EBCD) program in their members' health plans.

These medical groups, serving nearly 600,000 members across Southern California, will provide AI-powered breast cancer detection services to all mammogram-eligible patients. RadNet will implement a patient outreach program to boost compliance with annual screening guidelines. The program represents significant progress in securing EBCD reimbursement from commercial payors.

The collaboration aims to improve early breast cancer detection, as one in eight women will develop breast cancer in their lifetime. The AI-powered EBCD program can detect breast cancer earlier than traditional methods, potentially improving patient outcomes through earlier intervention.

RadNet (NASDAQ: RDNT) has acquired See-Mode Technologies, an AI innovator in ultrasound imaging diagnostics. See-Mode's FDA-approved AI solutions for thyroid and breast ultrasound detection will be integrated into RadNet's DeepHealth population health solutions. The acquisition demonstrates significant operational benefits, with early deployment showing up to 30% reduction in scan time across RadNet's imaging centers. RadNet performs approximately 250,000 annual thyroid ultrasounds and over two million total ultrasound studies yearly across 900+ units. The integration aims to improve diagnostic accuracy, enhance workflow efficiency, and generate standardized reports. The acquisition strengthens RadNet's position in AI-powered healthcare solutions, particularly in addressing thyroid and breast cancer diagnostics, which represent approximately 20 million ultrasound exams annually in the US alone.